HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase I study of N-methylformamide in patients with advanced cancer.

Abstract
N-Methylformamide (N-MF) belongs to a class of polar-planar compounds which induce cellular differentiation. Preclinical antitumor activity was demonstrated against human mammary, colon, and lung tumor xenografts and L1210 and P388 murine leukemias. This phase I study used a single bolus infusion of N-MF given weekly X 3 doses every 6 weeks. Thirty-five patients were treated with N-MF at doses which ranged from 125 to 3125 mg/m2/week. The dose-limiting toxic effects included nausea and vomiting, anorexia, malaise, and liver function abnormalities. No myelosuppression was seen. The recommended dose for phase II trials of N-MF with this schedule is to initiate therapy at 2000 mg/m2 weekly X 3 and escalate to 2500 mg/m2 if the initial dose was well tolerated.
AuthorsD S Ettinger, D W Orr, A P Rice, R C Donehower
JournalCancer treatment reports (Cancer Treat Rep) Vol. 69 Issue 5 Pg. 489-93 (May 1985) ISSN: 0361-5960 [Print] United States
PMID4005871 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antineoplastic Agents
  • Formamides
  • methylformamide
Topics
  • Adult
  • Aged
  • Anorexia (chemically induced)
  • Antineoplastic Agents (therapeutic use)
  • Drug Evaluation
  • Female
  • Formamides (adverse effects, therapeutic use)
  • Humans
  • Liver (drug effects)
  • Male
  • Middle Aged
  • Nausea (chemically induced)
  • Neoplasms (drug therapy)
  • Vomiting (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: